ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2912

Lupus Flare Activity from the Patient Perspective

Winnie Nelson1, Patricia Katz2, R. Paola Daly3, Lauren Topf3, Erin Connolly-Strong4 and Michael Reed5, 1Health Economics and Outcomes Research, Mallinckrodt Pharmaceuticals, Bedminster, NJ, 2University of California San Francisco, San Francisco, CA, 3Lupus Foundation of America, Washington, DC, 4Mallinckrodt ARD, Inc., Bedminster, NJ, 5Vedanta Research, Chapel Hill, NC

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Lupus and outcomes

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, October 24, 2018

Title: 6W007 ACR Abstract: Patient Outcomes, Preferences, & Attitudes II: PROs (2910–2915)

Session Type: ACR Concurrent Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose:

Lupus patients may experience flares in disease activity that require rapid management. This study describes the experience, identification, and management of a flare from the patient perspective.

Methods:

An online survey was administered to persons with lupus who responded to outreach from the Lupus Foundation of America or the Research Now survey research service. Data collection included sociodemographic characteristics, flare profile, the Lupus Impact Tracker (LIT), and hospital admissions. The results were summarized with descriptive statistics.

Results:

1503 individuals with self-reported lupus completed the survey from May to October 2017. 77% were Caucasian, 89% were female, mean age was 45 yrs, mean duration of illness was 12 yrs, and 19% reside rurally. 78% had flare activity in the past year. Of these, half reported 4 or more flares, and 66.9% perceived their flares as moderate to severe. The most common flare symptoms (Figure 1) were extreme fatigue/exhaustion (87%), aching/increased swelling of the joints (80%), and muscle weakness/pain (74%). Respondents who suffered more flares had worse LIT scores and more hospital admissions during the past year (Figure 2). Many respondents (48%) could not predict when a flare would occur but noted that flare triggers were events such as emotional stress, overdoing it, lack of rest, and sunlight exposure. 40.5% engaged the healthcare system, such as doctor, ER, or hospital, when suffering a flare. 54% self-treated flares, most frequently with over-the-counter products and prescription drugs kept on hand. For the most recent flare 34.8% delayed seeking care for 3 days or longer (24.3% of urban residents, 41.9% of rural); more than half did not receive care within 24 hours (46.1% of urban, 62.2% of rural). Figure 3 shows various tactics used to manage flares.

Conclusion:

Lupus flare burden is high, and flares often resulted in healthcare encounters and medication use. The most common flare symptoms may not be congruent with how clinicians define flares, leading to communication challenges. Patients appear to be receptive to self-treatment, presenting an opportunity to enhance their self-care skills. Findings provide insight into how clinicians and patients can work together to identify and manage flares more effectively.




Disclosure: W. Nelson, Mallinckrodt Pharmaceuticals, 1, 3; P. Katz, Mallinckrodt Pharmaceuticals, 5; R. P. Daly, Mallinckrodt Pharmaceuticals, 2; L. Topf, Mallinckrodt Pharmaceuticals, 2; E. Connolly-Strong, Mallinckrodt Pharmaceuticals, 1, 3; M. Reed, Mallinckrodt Pharmaceuticals, 5.

To cite this abstract in AMA style:

Nelson W, Katz P, Daly RP, Topf L, Connolly-Strong E, Reed M. Lupus Flare Activity from the Patient Perspective [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/lupus-flare-activity-from-the-patient-perspective/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lupus-flare-activity-from-the-patient-perspective/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology